Ionis Pharmaceuticals (IONS) gained attention as the FDA accepted its New Drug Application for zilganersen and granted Priority Review, advancing its Alexander disease program. Despite a remarkable one-year total shareholder return of 162.24%, recent shorter-term returns have been weaker, hinting at mixed investor sentiment.
Current trading at $74.79 is perceived as undervalued compared to a fair value estimate of $93.90, supported by a promising late-stage drug pipeline. However, with a significantly high price-to-sales ratio of 13.1, investor optimism could be overstated, raising questions about the sustainability of valuations amidst the company’s transition to a commercial stage.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/assessing-ionis-pharmaceuticals-ions-valuation-after-fda-pri
